Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk groups, as global HIV prevention efforts face funding setbacks ...

The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Key points Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show striking effectiveness across diverse populations at high risk for HIV.

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines durings the world's most influential meeting on HIV research and its ...